Patients, SCT features and complications developed post-SCT in the patients included in the present study.

D:donor; R:recipient; ALL: acute lymphoblastic leukemia; AML: acute myeloid leukemia; MDS: myelodysplastic syndrome; MM: multiple myeloma; CML: chronic myeloid leukemia AA: aplastic anemia CR: complete remision; TBI: total body irradiation.
(1) Unknown in 26 patients. GVHD: graft versus host disease; OS: overall survival.
(2) Patients at risk (alive and in complete remission) of developing: grade II-IV aGvHD n = 236. Patients censored n = 16 (11 relapsed and 5 dead); grade III-IV aGvHD III-IV n = 232. Patients censored n = 20 (13 relapsed and 7 dead).
(3) Patients at risk: cGvHD n = 200. Patients censored n = 52 (25 relapsed and 27 dead).
(4) Patients at risk: relapse n = 224. Patients censored n = 28 (relapsed in complete remission first year).
(5) Unknown n = 10
Patients, SCT features and complications developed post-SCT in the patients included in the present study.